Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic Rhinoconjunctivitis

Allergopharma

Status and phase: Completed; Phase 3

Conditions: Birch Pollen Allergy

Treatments: Biological: Recombinant birch pollen

Study type: Interventional

Funder types: Industry

Identifiers

NCT00309062

Al0103rB

Details and patient eligibility

About

Safety and efficacy of recombinant birch pollen allergen in the treatment of allergic rhinoconjunctivitis

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Positive Skin Prick Test reaction to birch pollen
• Positive RAST result to birch pollen
• Positive Provocation Test result to birch pollen

Exclusion criteria

• Serious chronic diseases
• Other perennial allergies

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind